MFDS restricts prescription of Hanmi Pharm’s 27th new Korean drug, ‘Olita Tab’
The 27th new Korean drug developed by Hanmi Pharm, ‘Olita Tab’ was restricted to prescribe for new patients as encountering to an adverse response which was not reflected in its clinical trials.
On the 30th, the Ministry of Food and Drug Safety(MFDS) announced distribution of a safety letter to...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
